BACKGROUND: No pharmacological therapy exists for calcific aortic valve disease (CAVD), which confers a dismal prognosis without invasive valve replacement. The search for therapeutics and early diagnostics is challenging because CAVD presents in multiple pathological stages. Moreover, it occurs in the context of a complex, multi-layered tissue architecture; a rich and abundant extracellular matrix phenotype; and a unique, highly plastic, and multipotent resident cell population.
C
alcific aortic valve disease (CAVD) resulting in aortic valve stenosis affects 25% of the population >65 years of age 1 and is the most common indication for invasive and costly valve replacement. Because no effective pharmacological therapy exists, 2 CAVD confers a high clinical and economic burden. The disease progression is rapid and, although initially indolent, it results in heart failure and premature death if left untreated. 3 The underlying mechanisms of CAVD remain incompletely identified, thereby limiting advances in biomedical research and clinical treatment in its earlier stages before cardiac damage. Owing to its high morbidity and mortality, a strong incentive exists to identify the key early molecular drivers contributing to the development of this disease.
Anatomically, the aortic valve (AV) possesses a 3-layer architecture: the collagenous fibrosa layer facing the aortic side of the valve, the intermediate glycosaminoglycan-rich spongiosa layer, and the elastin-enriched ventricularis on the ventricular side. 4 CAVD is marked by inflammatory infiltration, fibrotic extracellular matrix (ECM) synthesis by activated valvular interstitial cells (VICs), increased leaflet thickening and stiffness, and calcific mineral deposition. The resultant pathological remodeling ultimately impairs valve movement and obstructs blood flow across the narrowing valve orifice. 5 Mineralization predominantly originates at the base of the valve attachment to the aortic wall and in the fibrosa side of heart valve leaflets, and progresses toward the tip. 5 Distinct stages of disease progression are evident; a single AV leaflet may harbor nondiseased, fibrotic, and calcific areas. Together, this pathology leads to AV stenosis, left ventricular remodeling, and the onset of symptoms.
In healthy valves, VICs comprise mostly quiescent fibroblasts that maintain valvular homeostasis and physiological leaflet mechanical properties. Under pathological biochemical and biomechanical stimuli, VICs undergo differentiation toward myofibroblastic and osteoblastic phenotypes as a result of newly acquired expression of cytoskeletal or osteogenic genes. Myofibrogenesis drives ECM remodeling, fibrosis, and leaflet stiffening, 6 which, in turn, promote further myofibroblastic differentiation. Osteoblastic VICs actively deposit calcium-rich mineral, but the pathogenic mechanisms that trigger their maladaptive differentiation in vivo are unclear. To date, no complete ontology of VICs exists, and neither the relative contributions of VIC myofibrogenesis/osteogenesis to impaired valve function nor putative cross-talk between these 2 hallmarks of disease have been clearly elucidated.
Recent advances in protein-protein interactomebased systems biology and network medicine have shed novel light on interorgan interplay, revolutionized target discovery, and are uniquely suited to capture a global view of highly complex pathobiology. 7 Despite this promise, systems medicine has not yet been applied to CAVD. Heart valve research in humans has traditionally been hindered by high intra-and interdonor variability, a lack of accounting for the heterogeneous layered structure of the leaflet, and limitations of in vitro culture models. We hypothesized that using human AV samples in conjunction with a comprehensive holistic "macro-to-micro" approach encompassing (1) disease stage-associated regions (CAVD disease stages), (2) anatomic tissue microlayers (CAVD layers), and (3) VIC subtypes (CAVD VICs) would address prior limitations in temporal and spatial resolution, 8, 9 help to decipher the complexity of CAVD pathogenesis, and generate a highly specific dataset for subsequent novel systems biology investigations. Importantly, dissecting the molecular pathology from the tissue level, to tissue layers, and finally to layer-specific cells enabled the elucidation of the valvular proteome, encompassing highly abundant ECM proteins on the tissue level, down to the cellular fingerprints of the molecular CAVD pathology. Such an approach would address crucial questions with far-reaching implications for the field of CAVD research.
Furthermore, given the intricate anatomic structure and function of the AV, we used not only a holistic approach encompassing disease stages, but also multiple
Clinical Perspective
What Is New?
• First application of multi-omics and network medicine to calcific aortic valve disease (CAVD); • A high-resolution spatiotemporal atlas of the combined valvular tissue, layer, and cell proteome, and a comprehensive repository of molecular drivers of CAVD; • First demonstration of side-specific valve cellular calcification potential and identification of a novel layer-specific cell marker; • Comparative omics-based identification of optimal cell culture models to recapitulate in vivo valvular calcification; • Network-based disease comparison of CAVD with other human diseases reveals a novel protein-based disease ontology.
What Are the Clinical Implications?
• Identification of novel targets for diagnostic molecular clinical imaging and pharmacological intervention in early and advanced CAVD; • Network medicine-based rationale for putative utility of antifibrotic and anti-inflammatory therapeutics for the treatment of CAVD; • Roadmap for the multi-omics study of complex cardiovascular diseases.
complementary techniques to assess anatomic layers and heterogeneous cell populations to decode the complexities of the valvular pathobiology. 10 We used transcriptomics in conjunction with both label-free and labelbased proteomics, with subsequent mapping by tissue immunofluorescence, and multi-dimensional network analysis ( Figure 1A ). Network medicine thereafter aided in deriving biological insights from these omics datasets.
This study expedites the translation of basic research findings into the clinic by integrating postoperative molecular imaging and pathology with proteomics, transcriptomics, and network analysis, thereby creating the first integrated map of human CAVD. More broadly, we present a methodological blueprint that can be applied to multi-omics studies on a plethora of tissue types with complex tissue microarchitecture and temporal variation in disease evolution.
METHODS
Detailed methods are provided in the online-only Data Supplement. The data are available through https://cics.bwh. harvard.edu/multiomics_databases.
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Transcriptomics and Proteomics Sample Preparation
In total, 25 AVs were used in this study. AV leaflets were obtained from AV replacement surgeries for severe AV stenosis (Brigham and Women's Hospital [BWH] approved IRB protocol number: 2011P001703). Written informed consent was provided. In brief, human stenotic AVs were segmented into stages of disease progression: (1) nondiseased, (2) fibrotic, and (3) calcific under the guidance of near-infrared molecular imaging. Transition zones were excluded from all analyses. In total, 27 subsamples were prepared for label-free proteomics and 9 for transcriptomics. AVs obtained from 3 additional patients with severe AV stenosis were used for tissue layer tandem mass tagging proteomics, and AVs from autopsy donors served as controls. Anatomic layer-specificity was facilitated by laser capture microdissection.
Side-specific in vitro layer calcification potential was evaluated through a migration assay on AV leaflets from 8 additional patients with severe AV stenosis after inspection by a pathologist to distinguish the fibrosa from the ventricularis side, and calcification was assessed by Alizarin Red staining at day 21. All cells that underwent proteomics were cultured and passaged in vitro prior to protein collection.
AV whole tissue label-free peptide samples were examined with the Q Exactive mass spectrometer. AV tissue layer tandem mass tagging and in vitro migration label-free peptide samples were analyzed with the LTQ-Orbitrap Elite mass spectrometer (Table I and II in the online-only Data Supplement for TMT channel assignments and peptide recovery, respectively).
Statistical Analysis
For transcriptomics analysis of the AV whole tissue, we normalized the raw read count data using DESeq2. The Wald test of DESeq2 was used to compare RNA abundances and false discovery rate was used to adjust P values. We used median-normalization of the AUC for label free proteomics and sum-normalization of the 3 layers' reporter ion intensities for label-based proteomics. For CAVD Disease Stage and Layer proteomics, a protein was assigned to the a given stage/ layer if its normalized mean AUC fold change was greater than 1.2 with respect to the other stages/layers (see Methods in the online-only Data Supplement for a detailed description). For pathway analysis, the protein sets corresponding to each layer and stage were tested for enrichment by a hypergeometric test and adjusted for multiple comparisons using the BenjaminiHochberg method for controlling the false discovery rate.
RESULTS
Omics Studies of Disease Stages in CAVD
Global Transcriptional and Protein Expression Signatures Differ in Each CAVD Disease Stage AV leaflets were obtained from 12 patients undergoing surgical AV replacement due to aortic stenosis. To map the molecular expression signatures that associate with disease progression, with the aid of ex vivo molecular imaging we dissected each leaflet into the 3 segments: (1) grossly nondiseased (ND), which is typified by a thin, transparent and pliable appearance; (2) fibrotic, which is thicker and stiffer than the nondiseased segment; and (3) calcific, which is visualized with a near-infrared fluorescence calcium tracer ( Figure 1B) .
Transcriptomics (n=3 donors) and (label-free) whole tissue proteomics (n=9 donors) provided additional support for our CAVD stage classification ( Figure 1C ). For example, hierarchical clustering of the q-adjusted relative gene expression profiles (Methods in the onlineonly Data Supplement) demonstrated that the calcific stage is distinct from the nondiseased, with the fibrotic stage representing an intermediate profile. This notion is underscored by a principal component analysis plot ( Figure 1C, left) . Similarly, the proteomics data also captured these distinct stages and clearly demarcated nondiseased from calcific tissue ( Figure 1C, right) .
Consistent Trends and Dissimilarities in Gene and Protein Expression Across Disease Stages
To resolve the valve transcriptome and proteome into the 3 stages of disease, we determined the unique sets of transcripts and proteins overrepresented in each stage, where overrepresentation is defined as a ≥1.2-fold increase of 1 stage relative to both of the other 2 stages (Methods in the online-only Data Supplement). RNA sequencing revealed a total of 114 transcripts to be overrepresented in the nondiseased stage, 103 in the fibrotic stage, and 587 in the calcific stage relative to the other 2 stages ( Figure 1D , Figure I in Figure IIIa and IIIb in the online-only Data Supplement; Figure IIIc in the online-only Data Supplement for overlap). To our knowledge, this is the first report of such a correlation analysis in AV data. The low correlation observed between transcriptomics and proteomics data has been previously reported for other tissues and systems. 12, 13 Nonetheless, despite the limited overlap, we identified common novel molecules between the transcriptomics and proteomics datasets: nondiseased stage (ANXA3, BST1, FGL2, IL17D), fibrotic stage (AOC3, CCDC80, CILP, CRTAC1, GFAP, HTRA3, PCOLCE2, PLA2G2A, PRG4, TUBB2B), and calcific stage (A2M, CMA1, CORO1A, HCLS1, LCP1, MZB1, SERPI-NA1, VWF; Figure 1D ).
Overall, transcriptomics identified a higher proportion of overrepresented transcripts in the calcific stage, whereas proteomics identified similar proportions of overrepresented proteins in all stages ( Figure 1D ). The high proportion of calcific stage-overrepresented transcripts may indicate a more diverse cellular environment potentially because of infiltration of inflammatory cells that would be more readily detected by the high sensitivity of mRNA-sequencing, in contrast to the relatively lower limit in the dynamic range of a typical proteomics analysis.
14 Gene expression profiling is frequently used to investigate disease states; however, proteins are the major functional entity driving diseases, 15 for which reason we elected to pursue the remainder of the study with a specific focus on the valvular proteome. Figure 1G , with known calcification modulators in red). To define further the specific resident proteome of the calcific stage, we excluded previously identified human plasma proteins 17 ( Figure II in the online-only Data Supplement, panel 'Calcific stage, serum proteins excluded'). In the transcriptomics data, CD74, APOE, A2M, SPP1, LAPTM5, VWF, IBSP, and MMP9 were among the highly overrepresented genes in the calcific stage ( Figure  I in the online-only Data Supplement). These results indicate that, from the distinct proteins that have emerged thus far, we are able both to identify novel and to confirm known molecules, thus supporting our notion that distinct pathogenic stages exist in a single leaflet.
Unveiling the Valvular Proteome in 3 Disease
The Proteomes of Distinct Aortic Valve Microlayers
Anatomic Aortic Valve Microlayers Exhibit Unique Proteome Profiles
The AV can also be interrogated in yet another dimension. In addition to the pathological breakdown above, more information can be gleaned from the distinct anatomic microlayers of the valve helping to answer the lingering issue of the predominant disease susceptibility of the fibrosa layer. To assess the proteomes of the 3 AV layers (fibrosa, spongiosa, ventricularis), we examined leaflets from nondiseased valves from autopsy (n=2 donors) and CAVD valves from surgical explants for aortic stenosis (n=3 donors). A typical nondiseased valve is <1 mm in thickness; in contrast, fibrotic and calcified valves are significantly thicker 5 ( Figure IVa and IVb in the online-only Data Supplement indicates the color scheme used throughout Figure 2 ). The layer architecture is sig-
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nified by the collagen-rich fibrosa (yellow by Movat's staining), the proteoglycan-rich spongiosa (blue-green), and the elastin-rich ventricularis (black) ( Figure IVc in the online-only Data Supplement). CAVD valve thickening is primarily triggered by ECM remodeling and calcification expansion originating from the fibrosa layer. To obtain layer-specific protein profiles, we used laser-capture microdissection to excise each tissue layer ( Figure IVd in the online-only Data Supplement) for proteomics.
From the combined proteomics data (Methods in the online-only Data Supplement, tandem mass tagging proteomics), we quantified 1872 proteins, of which 856 were common across the tandem mass tagging subexperiments and analyzed further (Figure V in the online-only Data Supplement). Even across nondiseased and CAVD samples, the proteomes of the individual layers were conserved and distinct from one other, with the fibrosa layer being the most distinctive among the To determine which proteins define the individual layers, we filtered for proteins with a fold increase of at least 1.2 in 1 layer relative to both of the other 2 layers (as done for the CAVD stage data) using both nondiseased and CAVD samples ( Figure 2B ). The distribution of these layer-specific proteins was similar for the combined and individual sample types ( Figure 2B ). Specifically, in the nondiseased AVs, 126 proteins were overrepresented in the fibrosa, 95 in the spongiosa, and 232 in the ventricularis ( Figure 2B ). In the diseased AV samples 117, 83, and 131 proteins were overrepresented in the fibrosa, spongiosa, and ventricularis, respectively ( Figure 2B ).
We present the top 15 most enriched proteins per layer for the common distribution pie chart ( Figure 2B ; Figure 2C and Figure VI in the online-only Data Supplement for full list), and the top 40 proteins for the corresponding nondiseased and CAVD samples ( Figure 2D , Figures VII and VIII in the online-only Data Supplement for full lists). In the combined dataset, TIMP3, APOE, PRELP, VTN, C9, PRSS23, PCOLCE2, MFGE8, APOB, CLU, SULF1, CFHR5, C4BP8, ASPN, and HTRA1 dominate in the fibrosa layer. In the spongiosa, glial fibrillary acidic protein (GFAP) and the adipocyte marker FABP4 were among the highest overrepresented proteins. The ventricularis layer proteome was signified by myofibroblast activation markers (TPM2, MYH11, TAGLN, TPM4, and MYL6). The proteins are mapped to their respective quadrants in the principal component analysis plot (Figure 2C) , which was generated from the 856 common proteins (Figure 2A ).
To find proteins that are uniquely enriched in either nondiseased or CAVD samples, we performed a subanalysis on each sample type separately (Figure 2D) . Although the heatmap suggests a high degree of conservation in the proteome across the sample types, a closer inspection of the top 40 proteins reveals distinct differences. For example, a general trend toward a higher proportion of apolipoproteins in the diseased fibrosa and proteins signifying myofibroblast activation in the diseased ventricularis appears evident ( Figure 2D ). For a more systematic view of the differences between nondiseased and CAVD samples, we quantified the differential expression of all proteins within each layer ( Figure 2F ). In the fibrosa, DCN, APOB, APOM, APOC1, FN1, ANGPTL2, and PON1 were enriched in the diseased compared with the nondiseased samples, whereas the relative contribution of collagens was reduced ( Figure 2E ). In the diseased spongiosa, GFAP was higher in relative abundance compared to nondiseased samples (Figure 2E) , which is consistent with its enrichment in both the fibrotic stage transcriptome and proteome ( Figure 1D ). An enrichment of proteins signifying myofibroblast activation was observed in the diseased ventricularis (MYH11, TAGLN2, CNN1, TAGLN, MYLK, TPM2, and TPM4; Figure 2E ).
CAVD Pathway Enrichment Analysis
The wealth of information contained within the valvular proteomics data is best exploited by implementation of pathway and network analyses, thereby permitting us to investigate potential global disease pathways that promote CAVD. To highlight the shared proteins of the biological processes represented by these enriched pathways, we constructed pathway networks. These pathway networks can provide a global view of the multiple processes involved in CAVD where clusters of similar pathways emerge naturally as a result of strong interconnections between them, allowing us to gather the predominant biological themes in each respective stage or layer. We elected to focus the pathway network analysis on the calcific stage and the diseased fibrosa layer to study the most advanced disease phenotypes. By inspecting these densely interconnected clusters, the underlying biological processes can be inferred. 
CAVD Disease Progression Is Marked by an
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For example, the MAPK signaling cluster or subnetwork is based on the presence of pathways involved in MAPK family signaling cascades ( Figure X in the online-only Data Supplement), and the complement cluster comprised the complement cascade. Therefore, the overall network can be described as containing the following subnetworks: (1) MAPK signaling, (2) lipid metabolism, (3) coagulation, (4) complement system, (5) inflammation, and (6) ECM. The network representation of enriched pathways thus provides us with a concise overview of potential mechanisms underlying CAVD pathogenesis.
Proteins Overrepresented in the Diseased Fibrosa Are Functionally Annotated to Fibrosis and Calcification Pathways
Consistent with the approach from macro to micro, we next hypothesized that pathways implicated in the calcific stage would similarly appear in conjunction with the diseased fibrosa. Because calcification occurs preferentially in the fibrosa layer, 5 we focused on the diseased layers in the subsequent analyses and identified a total of 88 significantly enriched (q<0.05) pathways ( Figure 3B ; Figure XI in the online-only Data Supplement, Table IV in the online-only Data Supplement for the entire pathway list). A significant pathway enrichment was observed for integrin cell surface interactions, PI3K (phosphatidylinositol-3-kinase)/Akt signaling pathway, retinoid metabolism and transport, and regulators of bone mineralization, signifying a putative role in CAVD disease progression. The high enrichment of blood coagulation and oxidation-related pathways in the spongiosa suggests a novel and active involvement of this layer in disease progression ( Figure 3B ). Pathways with the highest enrichment scores in the diseased ventricularis were associated with smooth muscle contraction and (cardio) myopathy ( Figure 3B) . Consistent with the calcific stage pathway network (Figure X in the online-only Data Supplement), coagulation and complement pathways as well as lipoprotein-and ECM-related pathways were enriched in the CAVD fibrosa pathway network. In addition, PI3K-Akt signaling, endocrine system, platelet pathways, glycosaminoglycans, integrin-, and collagen-related pathways were the most prominent subnetworks ( Figure XII in the online-only Data Supplement).
Microlayer-Specific VIC Migration Proteome
The Microlayer-Specific Proteome Is Preserved in VICs Further progressing though our macro to micro view of the AV, we next focused on the VICs, the predominant valvular cell type. Current models posit that VIC osteogenic transition contributes to valvular calcifica- 
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tion. 18 Because valvular calcification is initiated in the fibrosa layer, we hypothesized that VICs from the fibrosa and ventricularis layers possess different phenotypes and distinct calcific potential. To test this hypothesis, we isolated fibrosa-and ventricularis-specific VIC populations by the outgrowth method ( Figure 4A ) from 8 CAVD donor leaflets and conducted an in vitro calcification assay ( Figure 4B ). To simulate valvular calcification in vitro, we used 2 commonly used calcifying media conditions. 19 In both alkaline phosphatase (ALPL)-dependent osteogenic medium (OM) and ALPL-independent procalcifying medium (PM) conditions, mineralization, as assessed by Alizarin Red staining, was enhanced in the fibrosa-derived VICs versus those from the ventricularis ( Figure 4B) .
We hypothesized that the difference in calcific potential is a consequence of the difference in the proteomes of VIC populations derived from either the fibrosa or the ventricularis. We first analyzed the baseline proteomes of the outgrown fibrosa and ventricularis VIC populations at their calcifying state (≈2 months in culture, passages 2-3). Inspecting their differentially expressed proteins ( Figure 4C ), we found 12 proteins that were significantly elevated in the ventricularis-VICs. In the fibrosa VICs, 24 proteins were overrepresented ( Figure 4C ). In the ventricularis VICs, the identified proteins were functionally annotated to glycolysis and gluconeogenesis and ECM organization, whereas the fibrosa VICs showed an association of their enriched proteome to mitochondrial, fatty acid, and ketone body-associated pathways, potentially pointing toward differences in metabolic state between fibrosa and ventricularis VICs ( Figure XIII in the online-only Data Supplement). We next mapped all of the overrepresented proteins per VIC layer origin (F/V FC<1/1.5) onto the PPI network and ranked them by their betweenness centrality (Methods in the online-only Data Supplement, Figures XIV and XV in the online-only Data Supplement). This analysis revealed a stress fiber-associated protein (ARF6) and the pro-to-oncogenes FYN and GSK3B to be of high centrality in fibrosa-VICs. EGFR, PRKCA, FN1, RPL21, and AKT1 projected the highest betweenness centrality in the ventricularis-VIC PPI network.
To further validate the cellular protein signatures, we compared the VIC proteomes from the fibrosa-and ventricularis-derived VICs with the tissue proteomes from the fibrosa and ventricularis layers ( Figure 4D ). Seven proteins were common to both the diseased fibrosa and fibrosa-derived VICs (APOE, ATP1B3, CO-L4A1, HAPLN1, SDCBP, SFRP4, TNC). In contrast, 14 proteins were shared by the ventricularis-VICs and their native tissue layer (AHNAK2, CAV1, CIRBP, EFEMP1, FERMT2, FHL1, HIST1H1B, LMNA, LMNB1, NID2, PAR-VA, SDPR, SORBS3, SRP14).
In Vitro Proteome of CAVD-Associated Stages
Calcifying VICs Have Distinct Proteome Profiles
After determining that fibrosa-derived VICs have higher calcification potential, we further evaluated their protein profiles under calcifying media conditions ( Figure 4E ). Using human primary VIC donors (n=2), we quantified the stimulated proteomes after 7 days of calcifying stimulation (Day 7, Figure 4F ). The q-adjusted relative protein abundance heat map demonstrated that the OM and PM proteomes were distinct both from each other and from that of control medium ( Figure 4F) .
We next sought to evaluate similarities between the calcification-prone fibrosa VIC proteomes (OM and PM; CAVD VICs dataset) and the calcific disease stage proteome ( Figure II in the online-only Data Supplement; CAVD disease stages). We filtered for proteins with a 1.2-fold increase of 1 medium condition relative to the other 2 ( Figure 4G ). OM and calcific disease stage overlapped with 13 proteins (including FN1), PM and calcific with 13 proteins (ie, AHSG and MMP2), and all 3 datasets shared 15 proteins (including TNC; Figure 4Gg ). This finding suggests that both media conditions simulate components of valvular calcification in vivo.
A closer look at the intersection between the CAVD disease stage transcriptomics (FPKM ≥1 in at least 1 stage), CAVD disease stage proteomics (≥2 unique peptides), and the VIC in vitro proteome (≥2 unique peptides) revealed a set of 133 proteins detected in whole tissue proteomics that were neither detected in the VIC proteomics nor in the CAVD disease stage transcriptomics ( Figure XVIa 
A Map of Human CAVD
This study identified several novel proteins that had not previously been implicated in the structure of normal and diseased AVs and the pathogenesis of CAVD. Based on the protein lists generated form the perspectives of the CAVD proteome, disease stages, and leaflet layers, we mapped the presence and expression of a subset of newly identified proteins via immunofluorescence staining and confocal microscopy. We first examined protein expression as a function of the CAVD stage ( Figure 5A-5C ).
In the nondiseased stage proteomics, COL1A1 was detected, and its presence also confirmed in non- Immunofluorescence of representative proteins for high layer specificity in the layer proteomics; ApoB, PRELP, SULF1, and PCOLCE2 were detected primarily in the fibrosa; GFAP specifically in the spongiosa; and CSRP1, CNN1, and AZGP1 in the ventricularis VICs. Scale bar, 100 µm.
We then mapped proteins across the layers (Figure 5D) . We confirmed expression of APOB, PRELP, SULF-1, and PCOLCE2 in the fibrosa layer, whereas CNN1, CSRP1, and AZGP1 were mapped onto VICs in the ventricularis layer ( Figure 5D ). Proteomics identified the astrocyte marker GFAP to be enriched in the spongiosa, in both the nondiseased and diseased AV leaflets ( Figure 2D ). Cardiac valves have previously been shown to harbor areas of GFAP-positivity. 21, 22 We determined by immunostaining that GFAP was cell-specific, and GFAP + /vimentin + cells were exclusively localized to the spongiosa ( Figure 5D ). This finding demonstrates the heterogeneous origin and phenotype of the mesenchymal VICs, is the first identification of a layer-specific VIC marker, and points toward a neural crest-derived origin of the spongiosa VIC population.
Human CAVD Networks and Disease Classification
To determine the key pathological contributors to CAVD by their physical interactions at the molecular level, we focused on the calcific stage ( Figure 1G ) and the CAVD fibrosa layer ( Figure 2D ) proteomes. We mapped their respective overrepresented proteins onto the human PPI network 23 comprising interactions with experimental evidence curated from multiple sources (Methods in the online-only Data Supplement). This analysis yielded the CAVD calcific stage ( Figure 6A ) and CAVD fibrosa layer ( Figure 6B) protein subnetworks. We then interrogated the biological importance of the proteins within these subnetworks by means of their betweenness centrality, which signifies the bottleneck nodes that are crucial to the communication within the network. 24 High betweenness centrality proteins are, hence, prominent intermediary proteins that have been shown to play essential functional and dynamical roles 7 as well as be potential drug targets. 25 We found that fibronectin-1 (FN1) played a pivotal role in both networks (Figure 6A and 6B; betweenness centrality ranked 1st in CAVD fibrosa network: 0.70; ranked 5th in CAVD calcific stage network: 0.27). Beside the prominent role of FN1 in both networks, PSMD3 and PSMA1 from the calcific stage network belong to the canonical transforming growth factor β-, canonical wnt-, MAPK and notch-signaling pathways, all of which have been shown to contribute to CAVD. THBS1 and DCN from the CAVD fibrosa network are part of the transforming growth factor β-signaling pathway, as well, and COL1A1 and ITGAV are annotated to osteoblast signaling, further highlighting that this network strategy yields relevant key molecules.
In light of the increasing evidence that disease proteins tend to form closely interacting subgraphs (disease modules) within the cellular interactome, and that disease-disease relationships can be uncovered from the network proximity of their disease modules, 23 we next sought to establish the association of CAVD with a diverse array of human diseases, including metabolic, cardiovascular, inflammatory, and malignant diseases (see Table VI in the online-only Data Supplement for a full list). Based on the average shortest (non-Euclidean) distance between disease modules (Methods in the online-only Data Supplement, Figure XVII in the online-only Data Supplement), we identified that vasculitis, dermatomyositis, systemic lupus erythematosus, pulmonary embolism, pulmonary fibrosis, intracerebral hemorrhage, Takayasu arteritis, hypercholesteremia, bronchiolitis obliterans, nonalcoholic fatty liver disease, atherosclerosis, myocardial infarction, and hypercholesteremia were closest 23 to the calcific stage subnetwork (empirical P<0.05; Figure 6C ; Figure XVIII in the onlineonly Data Supplement for the direct overlap between the calcific disease stage network and these diseases). These diseases fall under the categories of inflammatory and fibrotic diseases. 26 In contrast, oncological diseases did not possess significant closeness to the calcific stage module. In general, despite the current limitations regarding the incompleteness of the interactome, the proximal location of a disease to diseases in certain parts of the interactome and the lack of connectivity to diseases in other parts provides important clues about the pathobiological relationships between these diseases, because topologically overlapping or proximal diseases tend to show significant gene coexpression, symptom similarity, and comorbidity, whereas topologically separated diseases do not. These findings, hence, point toward shared pathogenic contributors between a subset of diseases and calcification in CAVD, and may ultimately enable a protein-based disease ontology. 23 
DISCUSSION
Advances in individual omics technologies and network medicine are revolutionizing preclinical and clinical medicine. As these high-throughput technologies mature, integration of multiple types of omics and subsequent downstream analyses into coherent and informative datasets that allow for conclusive answers to questions of causative changes in disease initiation, progression, and treatment is required. 27 CAVD is a prototypical disease that exists at the confluence of both highly complex pathophysiology and high clinical need. We present the first integrated atlas of the proteome and transcriptome of human CAVD, using a comprehensive undertaking that addresses the complexity of AV structural architecture and evolution of disease. We do so through incorporating macroscopic signatures of CAVD progression, anatomic layers, the in vitro VIC proteome, and cellular heterogeneity, followed by bioinformatics and multi-dimensional network analyses, and state-of- 
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the-art systems biology approach of disease categorization. Our macro (whole-tissue and microlayers) to micro (VICs) strategy allowed for a high degree of temporal and spatial resolution, whereas the global proteomics and transcriptomics analyses have enabled us to build unbiased expression profiles of the AV proteome across a wide-ranging set of experimental conditions. Furthermore, this macro to micro strategy allowed us to overcome the limitation of proteomics that highly abundant peptides are identified more readily than those with low abundance. High abundant plasma and matrix proteins that dominated the whole valve proteome became less prominent at the layer proteome and even lesser so at the VIC culture proteome, allowing us to uncover low abundant cellular-derived protein signatures of CAVD. This work provides an important new basis for hypothesis generation and mechanistic insight in heart valve pathobiology and allows for identification of novel pharmacological and imaging targets for early diagnosis and treatment of CAVD. Together, our multi-pronged omics assessment of CAVD has led us to a number of new insights into the pathobiology of this poorly understood disease. The enrichment in myofibrotic and calcification-related proteins and pathways validates our proposed regional approach and confirms that disease progression mapping is a valid technique on the level of a single heart valve leaflet. Identification of these annotated pathways may further guide the exploration of mechanisms governing CAVD and consideration of these pathways for pharmacological interventions to target CAVD. Our assessment of the stage-specific valvular proteome and transcriptome revealed classical fibrotic and calcific signatures. The fibrotic stage-specific proteome annotated pathways implicated players of early/fibrotic CAVD, including VIC myofibrogenesis 28 and oxidative stress. 29 In contrast, the calcific stage-specific network included a number of established modulators of valvular calcification, including ALPL, 19 AHSG, 30 APO(a) [LPA], 20 and APOB, 31 and was annotated to pathways known to be associated with VIC pathogenesis, including matrix metalloproteinase (MMP) activation 32 and MAPKsignaling. 33 The presence of these previously described proteins confirmed the relevancy of our multi-omics approach. We also observed a prominent inflammatory signal in both the diseased fibrosa proteome (eg, C8A, C8B, SLPI) and the calcific stage of CAVD (ELANE, HLA-DRA, MNDA, CD14, MPO), lending further credence to the debated notion that unresolved inflammation is a major contributor to human CAVD progression. 34 Importantly, our study identified several novel proteins that could serve as potential targets to treat CAVD during the stages of both fibrosis and calcification. Prior studies of valve pathobiology in animal models and cultured VICs have identified roles for individual components of MAPK signaling, 33 PI3K-Akt signaling, 35 lipoproteins/lipids, 20 and vesicular processes. 36 Here, we demonstrate for the first time both a degree of novel clustering and novel interconnectedness between these pathways in the human AV, thus establishing a basis for future investigations.
Data from histological studies of human CAVD using quantitative analysis of microcalcifications (precursors of macrocalcification 37 ) have suggested that calcification initiates from the fibrosa layer. 5 Despite this widely held view, until now there has been no layer-specific study of the valvular proteome. Our experimental approach allowed us to identify significant differences in the proteome of the calcification-prone fibrosa layer as compared with the spongiosa and ventricularis, and to establish the presence of layer-specific alterations in advanced CAVD. This discovery supports our hypothesis that both structural matrix (eg, FN1, VTN, PRELP, PCOL-CE2, COMP) and secreted (eg, TIMP3, CLU, HTRA1, TNC, SPARC) VIC proteins in the fibrosa contribute to its calcification propensity and suggest that proteins enriched in the fibrosa layer may be therapeutic targets to halt CAVD.
To identify VIC intracellular molecular drivers of AV calcification that could otherwise be masked by the highly abundant ECM in proteomics, we isolated VICs specifically from the fibrosa region and compared their calcific potential with VICs derived from the calcification-protected ventricularis in vitro. Consistent with our leaflet layer proteomes, we discovered a heightened predilection for calcification in VICs derived from the fibrosa layer, further implicating fibrosa-derived VICs as the main drivers for calcification in CAVD. As a first indication of dysfunction in the fibrosa, we identified differential metabolic programming in glycolytic and fatty-acid metabolism between layer-derived VIC populations. In addition, we showed that the proteome of the diseased fibrosa was rich in pathogenic pathways, including collagen biosynthesis and modification, 5 ECM degradation, 38 glycosaminoglycan metabolism, 39 and lipid metabolism. 40 Although the ventricularis is generally understood to be protected from disease development, perhaps because of high shear stresses on the ventricular side of the leaflet, 41 we identified a dysregulated myo-contractile response in the diseased ventricularis, consistent with a prior study that found greater upregulation of myofibrogenesis in ventricularis-derived VICs than those from the fibrosa on exposure to mechanical strain ORIGINAL RESEARCH ARTICLE or transforming growth factor β1 stimuli. 42 Although the ventricularis layer itself may not calcify, there remains the intriguing possibility that promyofibrogenic changes in this layer alter how cyclic mechanical forces are transmitted throughout the leaflet, contributing to pathological VIC differentiation in calcification-prone regions of the fibrosa.
Multiple calcifying media formulations exist in the CAVD literature. We provide evidence that culture models of VIC calcification which recapitulate either ALPL-mediated osteogenic calcification or ALPL-independent hyperphosphatemia associated with mineral imbalance (eg, chronic kidney disease 19 ) stimulates calcific proteomes in vitro and share a high degree of similarity with that of the calcific stage proteome in vivo. This finding suggests that investigation of both ALPL-mediated and ALPL-independent culture conditions will be important to future studies of cellular behaviors in CAVD.
Furthermore, our holistic omics approach followed by comprehensive multi-dimensional network analysis discovered several common proteins enriched in diseased stages and disease-prone layers. Among these is fibronectin-1, which was identified in both the CAVD fibrosa and calcific stage proteomes, as well as the corresponding betweenness-centrality-weighted PPI networks. Fibronectin-1 has previously been implicated in VIC myofibrogenesis in vitro because of its potential binding to transforming growth factor β1, 43 thus suggesting an additional novel role for fibronectin-1 in modulating valvular calcification, and demonstrating the potential of these networks for hypothesis generation. We further used this network approach to construct the first protein-based disease ontology of CAVD and compared it with 38 curated human disease modules. As a positive control, we showed significant overlap with calcification-related diseases. Of note, we found significant overlap between the CAVD disease module and those of a variety of fibrotic, inflammatory, and hypercholesterolemia disease modules. Our network analysis also identified a significant overlap between our CAVD calcific stage network and that of atherosclerosis. Although this overlap may appear contradictory given potentially different mechanisms of calcification between CAVD and atherosclerosis 44 and the unfavorable findings of a number of randomized clinical trials of statin treatment in CAVD, 45 statins have been shown to inhibit calcification in cultured VICs 46 and there are some indications that the application of statins to CAVD may require different temporal implementation than for atherosclerosis. 45, 47 This overlap may, therefore, motivate future studies of antifibrotic and anti-inflammatory drugs toward the treatment of CAVD.
The current study describes the first integrated molecular atlas of human CAVD. We provide evidence of multiple discrete, yet coexisting, pathological processes that may act in parallel to promote valvular fibrosis and calcification. Our assessment of disease stageand layer-specific proteomes is the first to our knowledge to examine CAVD with a tissue resolution beyond that of the whole organ, thereby elucidating key drivers of valvular mineralization within the region most predisposed to disease-the fibrosa. Furthermore, we show that VICs derived from the fibrosa and ventricularis are phenotypically and functionally different, with differential proteomes reflecting their profibrotic and procalcific potential. This work also identifies disease stage-and layer-specific VIC markers, including the GFAP-positive VIC phenotype as a specific marker for spongiosa VICs. Together, these fundamental results constitute the disease-specific protein network of the AV and provide a rich resource for future studies of human CAVD, thereby paving the way for clinically meaningful investigations and development of novel therapeutic and diagnostic imaging approaches that better address the intricate mixture of homeostatic and pathological processes at play in the AV. This framework for integration of spatiotemporal multi-omics and systems biology holds promise as a universal template for analysis of complex pathobiologies in a wide variety of disease states.
ARTICLE INFORMATION
Received October 16, 2017; accepted March 12, 2018.
The online-only Data Supplement is available with this article at https://www. ahajournals.org/journal/circ/doi/suppl/10.1161/circulationaha.117.032291.
